Survodutide
Extensamente estudadoDual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Dados moleculares e de pesquisa
- Sequência
- 29-amino acid peptide
- Peso molecular
- ~4,500 Da
- Meia-vida
- Approximately 6 days (109-115 hours)
- Alvos primários
- glp1-receptor
- Vias (pesquisa)
- injectable
- Armazenamento
- Reconstituted: 2-8°C immediately after mixing
Overview
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Mechanism of action
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
Key research findings
- Superior weight loss vs monotherapy (14.9% at 46 weeks)
- Once-weekly convenient dosing
- Proven efficacy in obesity, MASH, and Type 2 diabetes
- 62% MASH improvement in clinical trials
Research applications
Weight Loss
- Obesity Without Diabetes — 14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
- Obesity With Type 2 Diabetes — Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
- Sustained Weight Management — Dual mechanism addresses both energy intake and expenditure.
Metabolic
- MASH Treatment — 62% achieved MASH improvement without fibrosis worsening at 4.8mg.
- Liver Fat Reduction — 63-67% achieved ≥30% liver fat reduction.
- Type 2 Diabetes Control — HbA1c reduction up to -1.6% at highest doses.
FAQ de Survodutide
Why is survodutide superior to semaglutide for weight loss?+
Survodutide adds glucagon receptor agonism to GLP-1 effects, creating dual appetite suppression and energy expenditure increase. Head-to-head trials show -8.7% weight loss vs semaglutide's -5.3% at 16 weeks, because the glucagon pathway enhances fat burning independent of appetite.
Can survodutide reverse MASH (metabolic dysfunction-associated steatohepatitis)?+
Yes, clinical trials show 62% of MASH patients achieved improvement without fibrosis worsening at 4.8mg weekly, with 63-67% achieving ≥30% liver fat reduction. This makes it one of the first investigational agents with FDA potential for both MASH treatment and weight loss.
Is survodutide's 6-day half-life long enough for once-weekly dosing?+
Yes, the ~6-day half-life allows effective once-weekly dosing because peak levels remain therapeutic throughout the week. This contrasts with semaglutide (7-day half-life) - survodutide's slightly shorter half-life still covers the weekly interval adequately.
Does survodutide cause heart rate increases like other GLP-1 drugs?+
Survodutide shows a mean 2-5 bpm heart rate increase, similar to semaglutide. The glucagon receptor activation is modest enough to avoid significant tachycardia, though patients with cardiac conditions should monitor closely as with all GLP-1 agonists.
References
Peptídeos relacionados
5-Amino-1MQ
PreclinicalNNMT Inhibitor | Longevity & Metabolic Enhancement
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.
AOD-9604
Well studiedModified hGH Fragment | Fat Loss Peptide
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone.
BAM-15
Moderate researchMitochondrial Uncoupler | Metabolic Enhancer
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders.
Cagrilintide
Extensively studiedLong-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes.